All In Biotech

Investigational drug · Phase 2

coformulation pembrolizumab

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Small Cell Lung Carcinoma.

Phase 2

Last checked: Nov 20, 2026Latest source record: Jun 1, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

22

Any phase or sponsor naming "coformulation pembrolizumab"

First trial start

2021

Aug 19, 2021

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "coformulation pembrolizumab", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Small Cell Lung Carcinoma

Approved drugs for the same conditions: Oncology

Largest trials

Live from ClinicalTrials.gov: studies naming "coformulation pembrolizumab" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Small Cell Lung Carcinoma

  • R-DXdDS 6000a, MK-5909Phase 310 trials

    Merck & Co. · Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer

  • ObrixtamigBI 764532Phase 36 trials

    Boehringer Ingelheim · Small Cell Lung Cancer, Large Cell Neuroendocrine Lung Carcinoma, Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology

  • AL8326Phase 34 trials

    Advenchen Pharmaceuticals, LLC. · Endometrial Neoplasms, Soft Tissue Sarcoma (STS), Breast Neoplasms

  • coformulation favezelimabMK-4280APhase 33 trials

    Merck & Co. · Small Cell Lung Carcinoma, Solid Tumors, Hematologic Malignancies

  • MK-4830Phase 210 trials

    Merck & Co. · Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Esophageal Squamous Cell Carcinoma

  • CBX-12Phase 21 trial

    Cybrexa Therapeutics · Solid Tumor, Adult, Epithelial Ovarian Cancer, Small Cell Lung Carcinoma

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Merck & Co..

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.